U.S. markets open in 6 hours 22 minutes

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.11+0.16 (+0.59%)
At close: 04:00PM EDT
27.11 0.00 (0.00%)
After hours: 04:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close26.95
Bid0.00 x 800
Ask0.00 x 900
Day's Range26.50 - 27.59
52 Week Range23.15 - 34.50
Avg. Volume496,396
Market Cap1.448B
Beta (5Y Monthly)1.13
PE Ratio (TTM)20.63
EPS (TTM)1.31
Earnings DateAug 02, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SUPN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Supernus Pharmaceuticals, Inc.
    SUPN: Raising target price to $29.00SUPERNUS PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Supernus Announces First Quarter 2022 Financial Results

    First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter

  • GlobeNewswire

    Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

    ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call

  • American City Business Journals

    This MoCo biotech’s ADHD drug just earned FDA approval — this time, for adults

    Rockville’s Supernus Pharmaceuticals Inc. has earned regulatory approval for its attention deficit hyperactivity disorder drug for adults, more than a year after landing the green light to commercialize the product for kids. The Food and Drug Administration has given its nod to Qelbree as a treatment for ADHD in adults ages 18 and older, Supernus said Monday. The expansion of the approval, already in effect for children and adolescents ages 6 to 17, creates a new option for 16 million U.S. patients with ADHD.